W. Roock

发表

Colorectal Cancer Treated With Cetuximab Patients With Chemotherapy-Refractory Metastatic p . G 13 D Mutation With Outcome inKRASAssociation of Supplementary material

F. Nicolantonio, S. Khambata-Ford, J. Simes, 2010 .

Reply to C. Cremolini et al

S. Tejpar, B. Claes, B. Biesmans, 2010 .

6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium

S. Tejpar, W. Roock, 2009 .

KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab

C. Verslype, S. Tejpar, N. Personeni, 2007 .

Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

C. Stroh, Y. Humblet, S. Tejpar, 2008 .

New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC).

M. Delorenzi, T. Davison, S. Tejpar, 2010 .

Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series

A. Bardelli, A. Lièvre, P. Laurent-Puig, 2008 .

The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab

C. Stroh, Y. Humblet, S. Tejpar, 2008 .

Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data

A. Bardelli, A. Lièvre, P. Laurent-Puig, 2008 .

Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.

I. Çelik, Y. Humblet, S. Tejpar, 2008 .

High Amphiregulin and Epiregulin expression in K-ras wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease

I. Çelik, Y. Humblet, S. Tejpar, 2007 .

PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer

D. Lambrechts, B. Claes, E. Cutsem, 2009 .

PIK 3 CAMutations Are Not aMajor Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

D. Lambrechts, S. Tejpar, B. Claes, 2009 .

Clinical Biomarkers in Oncology Focus on Colorectal Cancer

S. Tejpar, B. Biesmans, W. Roock, 2012 .

Treated with Salvage Cetuximab / Panitumumab Monotherapy Improved Outcome in Patients with Metastatic Colorectal Cancer Predicts KRAS microRNA-Binding Site Polymorphism in let-7 A Updated

J. Weidhaas, P. Laurent-Puig, H. Lenz, 2014 .

Treatment of Zenker’s diverticulum through a flexible endoscope with a transparent oblique-end hood attached to the tip and a monopolar forceps

G. D'Haens, W. De Roock, W. Roock, 2007, Endoscopy.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

E. Van Cutsem, Y. Humblet, S. Tejpar, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Biomarkers in Oncology

S. Tejpar, W. De Roock, J. De Schutter, 2012, Molecular Diagnosis & Therapy.

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

M. Buyse, E. Van Cutsem, S. Tejpar, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.28 Dusp4 Expression as A Marker of Heterogeneous Signaling in Colorectal Cancer Patients

M. Delorenzi, I. Simon, S. Tejpar, 2012 .

DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease

P. Marynen, Y. Humblet, S. Tejpar, 2008 .